Extracellular vesicles (EVs) are a heterogeneous group of natural particles that are relevant
to the treatment of cardiovascular diseases. These endogenous vesicles have certain …

A large number of clinical trials have shown stem cell therapy to be a promising therapeutic
approach for the treatment of cardiovascular diseases. Since the first transplantation into …

Rationale: Paracrine secretions seem to mediate therapeutic effects of human CD34+ stem
cells locally transplanted in patients with myocardial and critical limb ischemia and in animal …

Diverse subsets of endothelial progenitor cells (EPCs) are used for the treatment of ischemic
diseases in clinical trials, and circulating EPCs levels are considered as biomarkers for …

Rationale: Transplantation of human CD34+ stem cells to ischemic tissues has been
associated with reduced angina, improved exercise time, and reduced amputation rates in …

Endothelial progenitor cells (EPCs) have been isolated and shown to be effective in animal
models of ischemia, and many groups involved in clinical trials have demonstrated that EPC …

Rationale: A growing number of patients with coronary disease have refractory angina.
Preclinical and early-phase clinical data suggest that intramyocardial injection of autologous …

Cardiovascular regenerative therapies are pursued on both basic and translational levels.
Although efficacy and value of cell therapy for myocardial regeneration can be debated …

Ischemic diseases characterized by an insufficient blood flow that leads to a decrease in
oxygen and nutrient uptake by cells have emerged as an important contributor to both …

The age-adjusted prevalence of peripheral arterial disease in the US population has been
estimated to approach 12%. The clinical consequences of occlusive peripheral arterial …